Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
June 26, 2026